Involvement and interactions of different immune cells and their cytokines in human visceral leishmaniasis

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 46, Issue 2, 2013, Pages 128-134

  Bhattacharya, Pradyot ^a   Ali, Nahid ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

Cytokines; Human visceral leishmaniasis; IL 10; Immunity

Indexed keywords

CHEMOKINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 27;

ADAPTIVE IMMUNITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE RESPONSE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOREACTIVITY; INNATE IMMUNITY; NATURAL KILLER CELL; NONHUMAN; PARASITE SURVIVAL; PARASITE VIABILITY; PARASITE VIRULENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; TH17 CELL; VISCERAL LEISHMANIASIS; ANIMAL; DISEASE COURSE; IMMUNOLOGY; MOUSE; REVIEW; T LYMPHOCYTE;

NASO HEXACANTHUS;

ANIMALS; CYTOKINES; DISEASE PROGRESSION; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, INNATE; LEISHMANIASIS, VISCERAL; MICE; T-LYMPHOCYTES;

EID: 84878602565     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/0037-8682-0022-2012     Document Type: Article

References (92)

1. Pourahmad M, Hooshmand F, Rahiminejad M. Cutaneous leishmaniasis associated with visceral leishmaniasis in a case of acquired immunodeficiency syndrome (AIDS). Int J Dermatol 2009; 48:59-61.
2. World Health Organization. Control of the leishmaniases. World Health Organization technical report series 2010; (949):xii-xiii, p. 1-186.
3. Caceresdittmar G, Tapia FJ, Sanchez MA, Yamamura M, Uyemura K, Modlin RL, et al. Determination of The Cytokine Profile In American Cutaneous Leishmaniasis using the Polymerase Chain-Reaction. Clin Exp Immunol 1993; 91:500-505.
4. Raziuddin S, Abdalla RE, Elawad EH, Aljanadi M. Immunoregulatory and Proinflammatory Cytokine Production in Visceral and Cutaneous Leishmaniasis. J Infect Dis 1994; 170:1037-1040.
5. Holaday BJ, Pompeu MMD, Jeronimo S, Texeira MJ, Sousa AD, Vasconcelos AW, et al. Potential Role for Interleukin-10 in the Immunosuppression Associated with Kala-Azar. J Clin Invest 1993; 92:2626-2632.
6. Bacellar O, Brodskyn C, Guerreiro J, BarralNetto M, Costa CH, Coffman RL, et al. Interleukin-12 restores interferon-gamma production and cytotoxic responses in visceral leishmaniasis. J Infect Dis 1996; 173:1515-1518.
7. Ghalib HW, Whittle JA, Kubin M, Hashim FA, Elhassan AM, Grabstein KH, et al. IL-12 Enhances Th1-Type Responses in Human Leishmania-donovani Infections. J Immunol 1995; 154:4623-4629.
8. Mary C, Auriault V, Faugere B, Dessein AJ. Control of Leishmania infantum infection is associated with CD8(+) and gamma interferon-and interleukin-5-producing CD4(+) antigen-specific T cells. Infect Immun 1999; 67:5559-5566.
9. Ghalib HW, Piuvezam MR, Skeiky YAW, Siddig M, Hashim FA, Elhassan AM, et al. Interleukin-10 Production Correlates with Pathology in Human Leishmania-donovani Infections. J Clin Invest 1993; 92:324-329.
10. Goto H, Gracas M. Immunoactivation and immunopathogeny during active visceral leishmaniasis. Rev Inst Med Trop Sao Paulo 2009; 51:241-246.
11. Saha S, Mondal S, Ravindran R, Bhowmick S, Modak D, Mallick S, et al. IL-10-and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: The significance of amphotericin B in the control of Leishmania donovani infection in India. J Immunol 2007; 179:5592-5603.
12. Mondal S, Bhattacharya P, Rahaman M, Ali N, Goswami RP. A Curative Immune Profile One Week after Treatment of Indian Kala-Azar Patients Predicts Success with a Short-Course Liposomal Amphotericin B Therapy. Plos Negl Trop Dis 2010; 4:e764.
13. Nylen S, Maurya R, Eidsmo L, Das Manandhar K, Sundar S, Sacks D. Splenic accumulation of IL-10 mRNA in T cells distinct from CD4(+) CD25(+) (Foxp3) regulatory T cells in human visceral leishmaniasis. J Exp Med 2007; 204:805-817.
14. Ansari NA, Saluja S, Salotra P. Elevated levels of interferon-gamma, interleukin-10, interleukin-6 during active disease in Indian kala azar. Clin Immunol 2006; 119:339-345.
15. Khoshdel A, Alborzi A, Rosouli M, Taheri E, Kiany S, Javadian MH. Increased Levels of IL-10, IL-12, and IFN-gamma in Patients with Visceral Leishmaniasis. Braz J Infect Dis 2009; 13:44-46.
16. Karp CL, Elsafi SH, Wynn TA, Satti MMH, Kordofani AM, Hashim FA, et al. Invivo cytokine profiles in patients with kala-azar-marked elevation of both interleukin-10 and interferon-gamma. J Clin Invest 1993; 91:1644-1648.
17. Kemp M, Kurtzhals JAL, Kharazmi A, Theander TG. Interferon-Gamma and Interleukin-4 in Human Leishmania-donovani Infections. Immunol Cell Biol 1993; 71:583-587.
18. Lagler H, Willheim M, Traunmuller F, Wahl K, Winkler H, Ramharter M, et al. Cellular profile of cytokine production in a patient with visceral leishmaniasis: gamma delta(+) T cells express both type 1 cytokines and interleukin-10. Scand J Immunol 2003; 57:291-295.
19. Hailu A, van Baarle D, Knol GJ, Berhe N, Miedema F, Kager PA. T cell subset and cytokine profiles in human visceral leishmaniasis during active and asymptomatic or sub-clinical infection with Leishmania donovani. Clin Immunol 2005; 117:182-191.
20. Ghosh M, Mandal L, Maitra S, Rakshit S, Paul K, Bagchi J, et al. Leishmania donovani infection of human myeloid dendritic cells leads to a Th1 response in CD4(+) T cells from healthy donors and patients with kala-azar. J Infect Dis 2006; 194:294-301.
21. Narayan S, Bimal S, Singh SK, Gupta AK, Singh VP, Sinha PK, et al. Leishmania donovani vs immunity: T-cells sensitized from Leishmania of one donor may modulate their cytokines pattern on re-stimulation with Leishmania from different donor in visceral leishmaniasis. Exp Parasitol 2009; 121:69-75.
22. Luz KG, Tuon FF, Duarte MIS, Maia GM, Matos P, Oliveira Ramos AM, et al. Cytokine expression in the duodenal mucosa of patients with visceral leishmaniasis. Rev Soc Bras Med Trop 2010; 43:393-395.
23. Ganguly S, Mukhopadhyay D, Das NK, Chaduvula M, Sadhu S, Chatterjee U, et al. Enhanced Lesional Foxp3 Expression and Peripheral Anergic Lymphocytes Indicate a Role for Regulatory T Cells in Indian Post-Kala-Azar Dermal Leishmaniasis. J Invest Dermatol 2010; 130:1013-1022.
24. Santos-Oliveira JR, Regis EG, Leal CRB, Cunha RV, Bozza PT, Da-Cruz AM. Evidence That Lipopolisaccharide May Contribute to the Cytokine Storm and Cellular Activation in Patients with Visceral Leishmaniasis. Plos Negl Trop Dis 2011; 5:e1198.
25. Rai AK, Thakur CP, Singh A, Seth T, Srivastava SK, Singh P, et al. Regulatory T Cells Suppress T Cell Activation at the Pathologic Site of Human Visceral Leishmaniasis. Plos One 2012; 7:e31551.
26. Maurya R, Kumar R, Prajapati VK, Manandhar KD, Sacks D, Sundar S, et al. Human visceral leishmaniasis is not associated with expansion or accumulation of Foxp3+CD4 cells in blood or spleen. Parasite Immunol 2010; 32:479-483.
27. Pitta MGR, Romano A, Cabantous S, Henri S, Hammad A, Kouriba B, et al. IL-17 and IL-22 are associated with protection against human kala azar caused by Leishmania donovani. J Clin Invest 2009; 119:2379-2387.
28. Ansari NA, Kumar R, Gautam S, Nylen S, Singh OP, Sundar S, et al. IL-27 and IL-21 Are Associated with T Cell IL-10 Responses in Human Visceral Leishmaniasis. J Immunol 2011; 186:3977-3985.
29. Peruhype-Magalhaes V, Martins-Filho OA, Prata A, Silva LD, Rabello A, Teixeira-Carvalho A, et al. Immune response in human visceral leishmaniasis: Analysis of the correlation between innate immunity cytokine profile and disease outcome. Scand J Immunol 2005; 62:487-495.
30. Hailu A, Van der Poll T, Berhe N, Kager PA. Elevated plasma levels of interferon (IFN)-gamma, IFN-gamma inducing cytokines, and IFN-gamma inducible CXC chemokines in visceral leishmaniasis. Am J Trop Med Hyg 2004; 71:561-567.
31. Caldas A, Favali C, Aquino D, Vinhas V, van Weyenbergh J, Brodskyn C, et al. Balance of IL-10 and interferon-gamma plasma levels in human visceral leishmaniasis: Implications in the pathogenesis. BMC Infect Dis 2005; 5:113.
32. Gama MEA, Costa JML, Pereira JCR, Gomes CMC, Corbett CEP. Serum cytokine profile in the subclinical form of visceral leishmaniasis. Braz J Med Biol Res 2004; 37:129-136.
33. Kurkjian KM, Mahmutovic A, Kehar KL, Haque R, Bern C, Secor WE. Multiplex analysis of circulating cytokines in the sera of patients with different clinical forms of visceral leishmaniasis. Cytometry A 2006; 69A:353-358.
34. Singh OP, Gidwani K, Kumar R, Nylen S, Jones SL, Boelaert M, et al. Reassessment of Immune Correlates in Human Visceral Leishmaniasis as Defined by Cytokine Release in Whole Blood. Clin Vaccine Immunol 2012; 19:961-966.
35. Kushawaha PK, Gupta R, Sundar S, Sahasrabuddhe AA, Dube A. Elongation Factor-2, a Th1 Stimulatory Protein of Leishmania donovani, Generates Strong IFN-gamma and IL-12 Response in Cured Leishmania-Infected Patients/ Hamsters and Protects Hamsters against Leishmania Challenge. J Immunol 2011; 187:6417-6427.
36. Nandan D, Oliveira CC, Moeenrezakhanlou A, Lopez M, Silverman JM, Subek J, et al. Myeloid Cell IL-10 Production in Response to Leishmania Involves Inactivation of Glycogen Synthase Kinase-3 beta Downstream of Phosphatidylinositol-3 Kinase. J Immunol 2012; 188:367-378.
37. Chandra D, Naik S. Leishmania donovani infection down-regulates TLR2-stimulated IL-12p40 and activates IL-10 in cells of macrophage/monocytic lineage by modulating MAPK pathways through a contact-dependent mechanism. Clin Exp Immunol 2008; 154:224-234.
38. Gautam S, Kumar R, Maurya R, Nylen S, Ansari N, Rai M, et al. IL-10 Neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis. J Infect Dis 2011; 204:1134-1137.
39. Ismail A, El Hassan AM, Kemp K, Gasim S, Kadaru A, Moller T, et al. Immunopathology of post kala-azar dermal leishmaniasis (PKDL): T-cell phenotypes and cytokine profile. J Pathol 1999; 189:615-622.
40. Mukhopadhyay D, Das NK, Roy S, Kundu S, Barbhuiya JN, Chatterjee M. Miltefosine effectively modulates the cytokine milieu in Indian Post Kala-Azar dermal leishmaniasis. J Infect Dis 2011; 204:1427-1436.
41. Katara GK, Ansari NA, Singh A, Ramesh V, Salotra P. Evidence for Involvement of Th17 Type Responses in Post Kala Azar Dermal Leishmaniasis (PKDL). Plos Negl Trop Dis 2012; 6:e1703.
42. Yoshimura T, Takeda A, Hamano S, Miyazaki Y, Kinjyo I, Ishibashi T, et al. Two-sided roles of IL-27: Induction of Th1 differentiation on naive CD4(+) T cells versus suppression of proinflammatory cytokine production including IL-23-Induced IL-17 on activated CD4(+) T cells partially through STAT3-dependent mechanism. J Immunol 2006; 177:5377-5385.
43. Wu W, Huang L, Mendez S. A live Leishmania major vaccine containing CpG motifs induces the de novo generation of Th17 cells in C57BL/6 mice. Eur J Immunol 2010; 40:2517-2527.
44. Vouldoukis I, Becherel PA, RiverosMoreno V, Arock M, daSilva O, Debre P, et al. Interleukin-10 and interleukin-4 inhibit intracellular killing of Leishmania infantum and Leishmania major by human macrophages by decreasing nitric oxide generation. Eur J Immunol 1997; 27:860-865.
45. Cheekatla SS, Aggarwal A, Naik S. mTOR signaling pathway regulates the IL-12/IL-10 axis in Leishmania donovani infection. Med Microbiol Immunol 2012; 201:37-46.
46. Peruhype-Magalhaes V, Martins-Filho OA, Prata A, Silva LDA, Rabello A, Teixeira-Carvalho A, et al. Mixed inflammatory/regulatory cytokine profile marked by simultaneous raise of interferon-gamma and interleukin-10 and low frequency of tumour necrosis factor-alpha(+) monocytes are hallmarks of active human visceral Leishmaniasis due to Leishmania chagasi infection. Clin Exp Immunol 2006; 146:124-132.
47. Diehl S, Rincon M. The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol 2002; 39:531-536.
48. Yamamoto M, Yoshizaki K, Kishimoto T, Ito H. IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol 2000; 164:4878-4882.
49. Ouyang W, Filvaroff E, Hu Y, Grogan J. Novel therapeutic targets along the Th17 pathway. Eur J Immunol 2009; 39:670-675.
50. Duarte MIS, Andrade Jr HF, Takamura CFH, Sesso A, Tuon FF. TGF-beta and mesenchymal hepatic involvement after visceral leishmaniasis. Parasitology 2009; 104:1129-1136.
51. Frade AF, Oliveira LC, Costa DL, Costa CHN, Aquino D, Van Weyenbergh J, et al. TGFB1 and IL8 gene polymorphisms and susceptibility to visceral leishmaniasis. Infect Genet and Evol 2011; 11:912-916.
52. Das S, Pandey K, Kumar A, Sardar AH, Purkait B, Kumar M, et al. TGF-beta(1) re-programs TLR4 signaling in L. donovani infection: enhancement of SHP-1 and ubiquitin-editing enzyme A20. Immunol Cell Biol 2012; 90:640-654.
53. Medeiros IM, Reed S, Castelo A, Salomão R. Circulating levels of sTNFR and discrepancy between cytotoxicity and immunoreactivity of TNF-alpha in patients with visceral leishmaniasis. Clin Microbiol Infect 2000; 6:34-37.
54. Duarte MIS, Tuon FF, Pagliari C, Kauffman MR, Brasil RA. Human visceral leishmaniasis expresses Th1 pattern in situ liver lesions. J Infect 2008; 57:332-337.
55. Karplus TM, Jeronimo SMB, Chang H, Helms BK, Burns TL, Murray JC, et al. Association between the tumor necrosis factor locus and the clinical outcome of Leishmania chagasi infection. Infect Immun 2002; 70:6919-6925.
56. Garg R, Barat C, Ouellet M, Lodge R, Tremblay MJ. Leishmania infantum Amastigotes Enhance HIV-1 Production in Cocultures of Human Dendritic Cells and CD4(+) T Cells by Inducing Secretion of IL-6 and TNF-alpha. Plos Negl Trop Dis 2009; 3:e441.
57. Ansari NA, Katara GK, Ramesh V, Salotra P. Evidence for involvement of TNFR1 and TIMPs in pathogenesis of post-kala-azar dermal leishmaniasis. Clin Exp Immunol 2008; 154:391-398.
58. Teixeira MJ, Teixeira CR, Andrade BB, Barral-Netto M, Barral A. Chemokines in host-parasite interactions in leishmaniasis. Trends Parasitol 2006; 22:32-40.
59. Sato N, Kuziel WA, Melby PC, Reddick RL, Kostecki V, Zhao WG, et al. Defects in the generation of IFN-gamma are overcome to control infection with Leishmania donovani in CC chemokine receptor (CCR) 5-, macrophage inflammatory protein-1 alpha-, or CCR2-deficient mice. J Immunol 1999; 163:5519-5525.
60. Cotterell SEJ, Engwerda CR, Kaye PM. Leishmania donovani infection initiates T cell-independent chemokine responses, which are subsequently amplified in a T cell-dependent manner. Eur J Immunol 1999; 29:203-214.
61. Ato M, Stager S, Engwerda CR, Kaye PM. Defective CCR7 expression on dendritic cells contributes to the development of visceral leishmaniasis. Nat Immunol 2002; 3:1185-1191.
62. Rousseau D, Demartino S, Anjuere F, Ferrua B, Fragaki K, Le Fichoux Y, et al. Sustained parasite burden in the spleen of Leishmania infantum-infected BALB/c mice is accompanied by expression of MCP-1 transcripts and lack of protection against challenge. Eur Cytokine Netw 2001; 12:340-347.
63. Holaday BJ. Role of CD8+T cells in endogenous interleukin-10 secretion associated with visceral leishmaniasis. Mem Inst Oswaldo Cruz 2000; 95:217-220.
64. Potestio M, D'Agostino P, Romano GC, Milano S, Ferlazzo V, Aquino A, et al. CD4(+) CCR5(+) and CD4(+) CCR3(+) lymphocyte subset and monocyte apoptosis in patients with acute visceral leishmaniasis. Immunology 2004; 113:260-268.
65. Bimal S, Singh SK, Sinha S, Pandey K, Sinha PK, Ranjan A, et al. Leishmania donovani: role of CD2 on CD4(+) T-cell function in Visceral Leishmaniasis. Exp Parasitol 2008; 118:238-246.
66. Hailu A, Pater JM, Kager PA, Van der Poll T. Increased expression of HIV co-receptor CXCR4 on CD4+T-cells in patients with active visceral leishmaniasis. Scand J Infect Dis 2004; 36:56-58.
67. Petter A, Shetty-Lee A, Kofler G, Heumer HP, Larcher C. Visceral leishmaniasis in an AIDS patient on successful antiretroviral therapy: Failure of parasite eradication despite increase in CD4(+) T-cell count but low CD8(+) T-cell count. Scand J Infect Dis 2001; 33:236-238.
68. Clarencio J, Oliveira CI, Favali C-L, Medina O, Caldas A, Costa CH, et al. Could the lower frequency of CD8+CD18+CD45RO+lymphocytes be biomarkers of human VL? Int Immunol 2009; 21:137-144.
69. Maroof A, Beattie L, Zubairi S, Svensson M, Stager S, Kaye PM. Posttranscriptional regulation of Il10 gene expression allows natural killer cells to express immunoregulatory function. Immunity 2008; 29:295-305.
70. Rai AK, Thakur CP, Seth T, Mitra DK. Early activated Th-1 type and dominantly diverse natural killer T (CD3(+)CD161(+)V alpha 24(-)) cells in bone marrow among visceral leishmaniasis patients. Int J Parasitol 2011; 41:1069-1077.
71. Alexander J, Brombacher F. T helper1/t helper2 cells and resistance/susceptibility to leishmania infection: is this paradigm still relevant? Front Immunol 2012; 3:80.
72. Katara GK, Ansari NA, Verma S, Ramesh V, Salotra P. Foxp3 and IL-10 Expression Correlates with Parasite Burden in Lesional Tissues of Post Kala Azar Dermal Leishmaniasis (PKDL) Patients. Plos Negl Trop Dis 2011; 5:e1171.
73. Wilke CM, Bishop K, Fox D, Zou W. Deciphering the role of Th17 cells in human disease. Trends Immunol 2011; 32:603-611.
74. Marwaha AK, Leung NJ, McMurchy AN, Levings MK. TH17 Cells in Autoimmunity and Immunodeficiency: Protective or Pathogenic? Front Immunol 2012; 3:129.
75. Bending D, Newland S, Krejci A, Phillips JM, Bray S, Cooke A. Epigenetic Changes at Il12rb2 and Tbx21 in Relation to Plasticity Behavior of Th17 Cells. J Immunol 2011; 186:3373-3382.
76. Charmoy M, Auderset F, Allenbach C, Tacchini-Cottier F. The Prominent Role of Neutrophils during the Initial Phase of Infection by Leishmania Parasites. J Biomed Biotechnol 2010; 2010:719361.
77. Lopez Kostka S, Dinges S, Griewank K, Iwakura Y, Udey MC, von Stebut E. IL-17 promotes progression of cutaneous leishmaniasis in susceptible mice. J Immunol (Baltimore, Md: 1950) 2009; 182:3039-3046.
78. Vargas-Inchaustegui DA, Xin L, Soong L. Leishmania braziliensis infection induces dendritic cell activation, ISG15 transcription, and the generation of protective immune responses. J Immunol 2008; 180:7537-7545.
79. Castilho TM, Goldsmith-Pestana K, Lozano C, Valderrama L, Saravia NG, McMahon-Pratt D. Murine model of chronic L. (Viannia) panamensis infection: Role of IL-13 in disease. Eur J Immunol 2010; 40:2816-2829.
80. Boaventura VS, Santos CS, Cardoso CR, de Andrade J, Dos Santos WLC, Clarencio J, et al. Human mucosal leishmaniasis: Neutrophils infiltrate areas of tissue damage that express high levels of Th17-related cytokines. Eur J Immunol 2010; 40:2830-2836.
81. Agallou M, Margaroni M, Karagouni E. Cellular vaccination with bone marrowderived dendritic cells pulsed with a peptide of Leishmania infantum KMP-11 and CpG oligonucleotides induces protection in a murine model of visceral leishmaniasis. Vaccine 2011; 29:5053-5064.
82. Fitzgerald DC, Ciric B, Touil T, Harle H, Grammatikopolou J, Das Sarma J, et al. Suppressive effect of IL-27 on encephalitogenic Th17 cells and the effector phase of experimental autoimmune encephalomyelitis. J Immunol 2007; 179:3268-3275.
83. McKinstry KK, Strutt TM, Buck A, Curtis JD, Dibble JP, Huston G, et al. IL-10 Deficiency Unleashes an Influenza-Specific Th17 Response and Enhances Survival against High-Dose Challenge. J Immunol 2009; 182:7353-7363.
84. Anderson CF, Stumhofer JS, Hunter CA, Sacks D. IL-27 Regulates IL-10 and IL-17 from CD4(+) Cells in Nonhealing Leishmania major Infection. J Immunol 2009; 183:4619-4627.
85. Rosas LE, Satoskar AA, Roth KM, Keiser TL, Barbi J, Hunter C, et al. Interleukin-27R (WSX-1/T-cell cytokine receptor) gene-deficient mice display enhanced resistance to Leishmania donovani infection but develop severe liver immunopathology. Am J Pathol 2006; 168:158-169.
86. Murray HW, Nathan CF. Macrophage microbicidal mechanisms in vivo: Reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J Exp Med 1999; 189:741-746.
87. Murray HW, Xiang ZY, Ma XJ. Short report: Responses to Leishmania donovani in mice deficient in both phagocyte oxidase and inducible nitric oxide synthase. Am J Trop Med Hyg 2006; 74:1013-1015.
88. White JK, Mastroeni P, Popoff JF, Evans CAW, Blackwell JM. Slc111a1-mediated resistance to Salmonella enterica serovar Typhimurium and Leishmania donovani infections does not require functional inducible nitric oxide synthase or phagocyte oxidase activity. J Leukoc Biol 2005; 77:311-320.
89. Perez LE, Chandrasekar B, Saldarriaga OA, Zhao W, Arteaga LT, Travi BL, et al. Reduced nitric oxide synthase 2 (NOS2) promoter activity in the Syrian hamster renders the animal functionally deficient in NOS2 activity and unable to control an intracellular pathogen. J Immunol 2006; 176:5519-5528.
90. Biswas A, Bhattacharya A, Kar S, Das PK. Expression of IL-10-triggered STAT3-dependent IL-4R alpha is required for induction of arginase 1 in visceral leishmaniasis. Eur J Immunol 2011; 41:992-1003.
91. Schleicher U, Liese J, Knippertz I, Kurzmann C, Hesse A, Heit A, et al. NK cell activation in visceral leishmaniasis requires TLR9, myeloid DCs, and IL-12, but is independent of plasmacytoid DCs. J Exp Med 2007;204:893-906.
92. Elshafie AI, Ahlin E, Hakansson LD, Elghazali G, El Safi SH, Ronnelid J, Venge P. Activity and turnover of eosinophil and neutrophil granulocytes are altered in visceral leishmaniasis. Int J Parasitol 2011; 41:463-469.